Table 4.
Univariate and multivariate analyses of risk factors for overall survival in 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer
| Characteristic | Unadjusted analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex (male/female) | 0.93 (0.764 to 1.13) | 0.46 | – | |
| Age (<60/≥60 years) | 1.54 (1.281 to 1.84) | <0.001 | 1.60 (1.28 to 1.98) | <0.001 |
| Tumor size (≤3/>3 cm) | 1.75 (1.41 to 2.17) | <0.001 | 0.92 (0.71 to 1.21) | 0.56 |
| Tumor location (upper/middle/lower) | 0.67 (0.61 to 0.75) | <0.001 | 0.79 (0.69 to 0.89) | <0.001 |
| Performance status (0/1/2) | 1.02 (0.85 to 1.23) | 0.84 | – | |
| Preoperative body weight loss (no/limited/severe) | 1.29 (1.13 to 1.47) | <0.001 | 1.20 (1.03 to 1.41) | 0.02 |
| Adjuvant chemotherapy (no/yes) | 0.86 (0.71 to 1.04) | 0.11 | – | |
| Histological grade (well/poorly differentiated) | 1.28 (1.03 to 1.61) | 0.03 | 1.49 (1.10 to 2.02) | 0.009 |
| Metastatic lymph node ratio (<0.1/≥0.1) | 4.26 (3.38 to 5.36) | <0.001 | 2.04 (1.44 to 2.89) | <0.001 |
| TNM stage (I/II/III) | 3.29 (2.68 to 4.04) | <0.001 | 1.92 (1.42 to 2.60) | <0.001 |
| Neutrophils (<7.5/≥7.5×109/L) | 2.00 (1.46 to 2.73) | <0.001 | – | |
| Llymphocytes (<3/≥3×109/L) | 0.93 (0.64 to 1.35) | 0.70 | – | |
| Platelet (<400/≥400×109/L) | 0.94 (0.67 to 1.33) | 0.72 | – | |
| CRP (≤10/>10 mg/L) | 1.89 (1.47 to 2.43) | <0.001 | 1.18 (0.90 to 1.56) | 0.24 |
| Albumin (<35/≥35 g/L) | 1.59 (1.22 to 2.063) | 0.001 | – | |
| NLR (<2.3/≥2.3) | 1.66 (1.39 to 1.99) | 0.001 | – | |
| PLR (<117/≥117) | 1.28 (1.06 to 1.54) | 0.009 | 1.04 (0.82 to 1.32) | 0.75 |
| GPS (0/1/2) | 1.60 (1.37 to 1.89) | <0.001 | – | |
| COA-NLR (0/1/2) | 1.54 (1.34 to 1.77) | <0.001 | 1.35 (1.12 to 1.63) | 0.002 |
Abbreviations: CI, confidence interval; COA-NLR, the combination of albumin level and neutrophil lymphocyte ratio; CRP, C-reactive protein; GPS, Glasgow prognostic score; HR, hazard ratio; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; TNM, tumor–node–metastasis staging.